BMY vs CTNM · P/E 17, rev $24.46B vs $429.6M cap
Bristol-Myers Squibb Company (BMY) versus Contineum Therapeutics, Inc. Class A Common Stock (CTNM) — a side-by-side from cached financials, not a winner call.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Christopher S. Boerner Ph.D..
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) is a biotechnology company listed on US.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Latest reported CTNM revenue for 2024-09-30 was $0. Net income was -$27.7M. CTNM currently screens at market cap $429.6M.
BMY currently screens at market cap $95.36B and trailing P/E 17.5. CTNM currently screens at market cap $429.6M.
Not investment advice. Open the BMY and CTNM stock pages for the full models.
Not investment advice.